Coming back to some of @zeynep’s points:
I fully agree that the global community is not good at doing rapid applied research to inform recommendations, ref masks, schools, rapid tests. And we need to approach this question with a sense of urgency. 1/
-
-
Also think of what UK/NHS did (and give us dexa!) and what we did not do here—randomize and do clinical trials even when we didn't know what was what. We could have done cluster studies for masks/hepa filters/ventilation etc. too.
-
Also immunologists raise durability & high-risk groups—I get it, very real concerns—but a lot of the broader conversation is already mired in that 52.4% efficacy figure and the statistical illiteracy already surrounding it. I'm hoping we move to conversation to the real issues!
- Show replies
New conversation -
-
-
Options need to be considered given issues with AstraZeneca, which was expected to provide majority of vaccine for the US. *Use a 6 week interval, take chance next batch doesn't arrive * Use smaller 2nd dose. * Use 2/3 dose. In a month, this could save 10-20k lives.
-
So risk wasting all the vaccine using an untested regimen. That’s the downside here, to be very clear.
- Show replies
New conversation -
-
-
The possibility of a vaccine scarcity in the midst of raging epidemic should have been considered in May. There should have been plans A, B, C, D Zeta etc etc. Another question we need to ask is what can we do to make more of this stuff NOW.
-
Of course they considered it. The reason the trials were done like this is very justified.
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.